Brand Name | Status | Last Update |
---|---|---|
fludarabine | ANDA | 2024-10-14 |
fludarabine phosphate | unapproved drug for use in drug shortage | 2023-07-25 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
non-hodgkin lymphoma | — | D008228 | C85.9 |
b-cell chronic lymphocytic leukemia | — | D015451 | C91.1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 10 | 14 | 2 | 1 | 2 | 22 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 4 | 1 | 1 | 1 | 7 |
Lymphoid leukemia | D007945 | — | C91 | 1 | 2 | 1 | 1 | 1 | 6 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloid leukemia acute | D015470 | — | C92.0 | 6 | 7 | 1 | — | — | 11 |
Myeloid leukemia | D007951 | — | C92 | 6 | 7 | 1 | — | — | 11 |
Myelodysplastic syndromes | D009190 | — | D46 | 5 | 7 | 1 | — | — | 9 |
Preleukemia | D011289 | — | — | 5 | 6 | 1 | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 3 | — | — | — | 4 |
Syndrome | D013577 | — | — | 2 | 4 | — | — | — | 4 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 3 | — | — | — | 4 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 2 | — | — | — | 3 |
Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | — | 3 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 1 | — | — | — | 1 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | 1 | — | — | — | 1 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | 1 | — | — | — | 1 |
Residual neoplasm | D018365 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | — | — | — | — | 1 |
Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | — | — | — | — | 1 |
Sclerosis | D012598 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell leukemia | D015448 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Fludarabine phosphate |
INN | fludarabine |
Description | (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol is a purine nucleoside. |
Classification | Small molecule |
Drug class | antineoplastics (arabinofuranosyl derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O |
PDB | — |
CAS-ID | 75607-67-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1096882 |
ChEBI ID | 63599 |
PubChem CID | 657237 |
DrugBank | DB01073 |
UNII ID | P2K93U8740 (ChemIDplus, GSRS) |